Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $15.0

First positive Phase 3 results for WELIREG from LITESPARK-005 showed statistically significant improvements in

KEYTRUDA significantly improved DFS as adjuvant therapy versus observation for patients with localized MIUC and

KEYTRUDA® (pembrolizumab) is the first anti-PD-1 therapy to demonstrate statistically significant improvement in

Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep

Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion

KEYTRUDA is the first therapy to show a statistically significant improvement in OS as adjuvant

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases Merck (NYSE: MRK

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter

Acquisition includes Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age